Inter-institutional comparison of personalized risk assessments for second malignant neoplasms for a 13-year-old girl receiving proton versus photon craniospinal irradiation

dc.contributor.authorTaddei, Phillip J.
dc.contributor.authorKhater, Nabil
dc.contributor.authorZhang, Rui
dc.contributor.authorGeara, Fady B.
dc.contributor.authorMahajan, Anita
dc.contributor.authorJalbout, Wassim T.
dc.contributor.authorPérez-Andújar, Angélica
dc.contributor.authorYoussef, Bassem Y.
dc.contributor.authorNewhauser, Wayne David
dc.contributor.departmentRadiation Oncology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:12:20Z
dc.date.available2025-01-24T12:12:20Z
dc.date.issued2015
dc.description.abstractChildren receiving radiotherapy face the probability of a subsequent malignant neoplasm (SMN). In some cases, the predicted SMN risk can be reduced by proton therapy. The purpose of this study was to apply the most comprehensive dose assessment methods to estimate the reduction in SMN risk after proton therapy vs. photon therapy for a 13-year-old girl requiring craniospinal irradiation (CSI). We reconstructed the equivalent dose throughout the patient’s body from therapeutic and stray radiation and applied SMN incidence and mortality risk models for each modality. Excluding skin cancer, the risk of incidence after proton CSI was a third of that of photon CSI. The predicted absolute SMN risks were high. For photon CSI, the SMN incidence rates greater than 10% were for thyroid, non-melanoma skin, lung, colon, stomach, and other solid cancers, and for proton CSI they were non-melanoma skin, lung, and other solid cancers. In each setting, lung cancer accounted for half the risk of mortality. In conclusion, the predicted SMN risk for a 13-year-old girl undergoing proton CSI was reduced vs. photon CSI. This study demonstrates the feasibility of inter-institutional whole-body dose and risk assessments and also serves as a model for including risk estimation in personalized cancer care. © 2015 by the authors; licensee MDPI, Basel, Switzerland.
dc.identifier.doihttps://doi.org/10.3390/cancers7010407
dc.identifier.eid2-s2.0-84924633589
dc.identifier.urihttp://hdl.handle.net/10938/32719
dc.language.isoen
dc.publisherMDPI AG
dc.relation.ispartofCancers
dc.sourceScopus
dc.subjectCraniospinal irradiation
dc.subjectHealth care disparities
dc.subjectPediatric medulloblastoma
dc.subjectProton therapy
dc.subjectSecond malignant neoplasm risk
dc.subjectAdolescent
dc.subjectArticle
dc.subjectCancer incidence
dc.subjectCancer mortality
dc.subjectCase report
dc.subjectColon cancer
dc.subjectComparative study
dc.subjectFemale
dc.subjectHuman
dc.subjectInstitutional care
dc.subjectLung cancer
dc.subjectMedulloblastoma
dc.subjectNon melanoma skin cancer
dc.subjectPersonalized medicine
dc.subjectPhoton therapy
dc.subjectRadiation dose
dc.subjectRisk assessment
dc.subjectRisk factor
dc.subjectRisk reduction
dc.subjectSecond cancer
dc.subjectSolid tumor
dc.subjectStomach cancer
dc.subjectSubsequent malignant neoplasm
dc.subjectThyroid cancer
dc.titleInter-institutional comparison of personalized risk assessments for second malignant neoplasms for a 13-year-old girl receiving proton versus photon craniospinal irradiation
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2015-10336.pdf
Size:
1.22 MB
Format:
Adobe Portable Document Format